PDCD1 and neoplasm: SGT-53 sensitized the efficacy of anti-PD1 antibody treatment via promotion of tumor immunogenicity, enhancement of innate and adaptive immune responses and inhibited immunosuppression in a breast tumor model (Kim et al., 2018).